Bortezomib is typically administered via injection. It can be given intravenously or subcutaneously, with the latter option often preferred due to a reduced risk of peripheral neuropathy. The treatment schedule usually involves cycles of administration followed by a rest period, allowing the patient's body to recover. Dosing and schedule are determined based on the specific cancer being treated and the patient's overall health.
